Interaction of the renal amylin and renin-angiotensin systems in animal models of diabetes and hypertension

Mineral and Electrolyte Metabolism

Volumn 24, Issue 6, 1998, Pages 389-399

  Wookey, P J ^a   Cao, Z ^b   Cooper, M E ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NONE

Author keywords

Amylin; Development; Diabetes; Growth factors; Kidney; Renin angiotensin system

Indexed keywords

AMYLIN; ANGIOTENSIN; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; HORMONAL REGULATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; TISSUE DISTRIBUTION;

EID: 0345355157     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057400     Document Type: Review

References (113)

1. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987;84:8628-8632.
2. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987;84: 3881-3885.
3. Johnson KH, O'Brien TD, Hayden DW, Jordan K, Ghobrial HKG, Mahoney WC, Westermark P: Immunolocalisation of islet amyloid polypeptidc (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein-A gold techniques. Am J Pathol 1988;130:1-8.
4. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky JGJ, Porte D Jr: Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 1990; 39:634-638.
5. Stridsberg M, Sandler S, Wilander E: Cosecretion of islet amyloid polypeptide (IAPP) and insulin from isolated rat pancreatic islets following stimulation or inhibition of beta-cell function. Regul Pept 1993;45:363-370.
6. Fehmann HC, Weber V, Goke R, Goke B, Arnold R: Cosecretion of amylin and insulin from isolated rat pancreas. FEBS Lett 1990;262:279-281.
7. Mulder H, Lindh AC, Sundler F: Islet amyloid polypeptide gene expression in the endocrine pancreas of the rat: A combined in situ hybridization and immunocytochemical study. Cell Tissue Res 1993;274:467-474.
8. Mulder H, Ahren B, Sundler F: Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. Mol Cell Endocrinol 1995;114:101-109.
9. Blackard WG, Clore JN, Kellum JM: Amylin/insulin secretory ratios in morbidly obese man - Inverse relationship with glucose disappearance rate. J Clin Endocrinol Metab 1994;78:1257-1260.
10. Williams AJ, Coates PJ, Lowe DG, McLean C, Gale EA: Immunochemical investigation of insulinomas for islet amyloid polypeptide and insulin: Evidence for differential synthesis and storage. Histopathology 1992;21:215-223.
11. Mulder H, Lindh AC, Ekblad E, Westermark P, Sundler F: Islet amyloid polypeptide is expressed in endocrine cells of the gastric mucosa in the rat and mouse. Gastroenterology 1994; 107:712-719.
12. Mulder H, Leckstrom A, Uddman R, Ekblad E, Westermark P, Sundler F: Islet amyloid polypeptide (amylin) is expressed in sensory neurons. J Neurosci 1995;15:7625-7632.
13. Wookey PJ, Tikellis C, Nobes M, Casley D, Cooper ME, Darby IA: Amylin as a growth factor during foetal and postnatal development of the rat kidney. Kidney Int 1998;53:25-30.
14. Badman MK, Shennan KIJ, Jermany JL, Docherty K, Clark A: Processing of pro-islet amyloid polypeptide (proiapp) by the prohormone convertase pc2. FEBS Lett 1996;378:227-231.
15. Cooper GJ: Amylin compared with calcitonin gene-related peptide: Structure, biology, and relevance to metabolic disease. Endocr Rev 1994; 15:163-201.
16. Miyazato M, Nakazato M, Shiomi K, Aburaya J, Toshimori H, Kangawa K, Matsuo H, Matsukura S: Identification and characterization of islet amyloid polypeptide in mammalian gastrointestinal tract. Biochem Biophys Res Commun 1991;181:293-300.
17. Skofitsch G, Wimalawansa SJ, Jacobowitz DM, Gubisch W: Comparative immunohistochemical distribution of amylin-like and calcitonin gene-related peptide-like immunoreactivity in the rat central nervous system. Can J Physiol Pharmacol 1995;73:945-956.
18. Banks WA, Kastin AJ, Maness LM, Huang WT, Jaspan JB: Permeability of the blood-brain barrier to amylin. Life Sci 1995;57:1993-2001.
19. Van Rossum D, Hanisch U-K, Quirion R: Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997;21:649-678.
20. Luebke AE, Dahl GP, Roos BA, Dickerson IM: Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. Proc Natl Acad Sci USA 1996;93:3455-3460.
21. Wookey PJ, Tikellis C, Du H-C, Qin H-F, Sexton PM, Cooper ME: Amylin binding in rat renal cortex, stimulation of adenylyl cyclase and activation of plasma renin. Am J Physiol 1996; 270:F289-F294.
22. Beaumont K, Kenney MA, Young AA, Rink TJ: High affinity amylin binding sites in rat brain. Mol Pharmacol 1993;44:493-497.
23. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K: In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 1994;62:553-567.
24. 125I]Bolton-Hunter rat amylin binding sites in the rat brain. J Pharmacol Exp Thcr 1994;270:779-787.
25. 1 and stimulates the release of pancreatic digestive enzymes from rat acinar AR42J cells: Evidence for an exclusive receptor system of amylin. Peptides 1996;17: 497-502.
26. Chantry A, Leighton B, Day AJ: Cross-reactivity of amylin with calcitonin gene-related peptide binding sites in rat liver and skeletal muscle membranes. Biochem J 1991;277:139-143.
27. Bhogal R, Smith DM, Bloom SR: Solubilization of binding sites for IAPP and CGRP from rat lung. Peptides 1994;15:1383-1390.
28. Lin HY, Harris TL, Flannery MR, Arrufo A, Kaji EH, Gorn A, Kolakowski LF Jr, Lodish HF, Goldring SR: Expression cloning and characterization of a porcine renal calcitonin receptor. Science 1991;254:1022-1024.
29. Kapas S, Catt K, Clark AJ: Cloning and expression of a cDNA encoding a rat adrenomedullin receptor. J Biol Chem 1995;270:25337-25344.
30. Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, Li Y: A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem 1996;271:11325-11329.
31. Kapas S, Clark AJ: Identification of an orphan receptor gene as a type 1 calcintonin gene-related peptide receptor. Biochem Biophys Res Commun 1995;217:832-838.
32. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 1994;37:188-194.
33. Huang HJ, Young AA, Koda JE, Tulp OL, Johnson MJ, Cooper GJ: Hyperamylinemia, hyperinsulinemia, and insulin resistance in genetically obese LA/N-cp rats. Hypertension 1992; 19:1101-1109.
34. Young DA, Deems RO, Deacon RW, McIntosh RH, Foley JE: Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol 1990;259:E457-E461.
35. Young AA, Wang MW, Cooper GJ: Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett 1991;291:101-104.
36. Young AA, Mott DM, Stone K, Cooper GJ: Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat. FEBS Lett 1991;281:149-151.
37. Young AA: Amylin regulation of fuel metabolism. J Cell Biochem 1994;55:12-18.
38. Young A, Pittner R, Gedulin B, Vine W, Rink T, Smith DM, Bloom SR, Slack JMW: Amylin regulation of carbohydrate metabolism. Biochem Soc Trans 1995;23:325-331.
39. Deems RO, Deacon RW, Young DA: Amylin activates glycogen phosphorylase and inactivates glycogen synthase via a cAMP-independent mechanism. Biochcm Biophys Res Commun 1991;174:716-720.
40. Ciaraldi TP, Goldberg M, Odom R, Stolpe M: In vitro effects of amylin on carbohydrate metabolism in liver cells. Diabetes 1992;41:975-981.
41. Clark A, Charge SBP, Badman MK, Dekoning EJP: Islet amyloid in type 2 (non-insulin dependent) diabetes. APMIS 1996;104:12-18.
42. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994;368:756-760.
43. Chance WT, Balasubramaniam A, Zhang FS, Wimalawansa SJ, Fischer JE: Anorexia following the intrahypothalamic administration of amylin. Brain Res 1991;539:352-354.
44. Chance WT, Balasubramaniam A, Chen X, Fischer JE: Tests of adipsia and conditioned taste aversion following the intrahypothalamic injection of amylin. Peptides 1992;13:961-964.
45. Chance WT, Balasubramaniam A, Thomas I, Fischer JE: Amylin increases transport of tyrosine and tryptophan into the brain. Brain Res 1992;593:20-24.
46. Chance WT, Balasubramaniam A, Stallion A, Fischer JE: Anorexia following the systemic injection of amylin. Brain Res 1993;607:185-188.
47. Clementi G, Valerio C, Emmi I, Prato A, Drago F: Behavioral effects of amylin injected intracerebroventricularly in the rat. Peptides 1996;17: 589-591.
48. Bouali SM, Wimalawansa SJ, Jolicoeur FB: In vivo central actions of rat amylin. Regul Pept 1995;56:167-174.
49. Flood JF, Morley JE: Differential effects of amylin on memory processing using peripheral and central routes of administration. Peptides 1992;13:577-580.
50. Young AA, Gedulin B, Vine W, Percy A, Rink TJ: Gastric emptying is acelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995;38:642-648.
51. Young A, Jodka C, Green D, Gedulin B, Obrien TD, Wagner JD, Litwak KN, Carlson CS, Cefalu WT, Jordan K, Johnson KH, Butler PC: Amylin inhibition of gastric emptying is reversed by hypoglycemia in rats. Diabetologia 1996;39:55.
52. Clementi G, Caruso A, Cutuli VMC, Debernardis E, Prato A, Amicoroxas M: Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Experientia 1996;52:677-679.
53. Arnelo U, Blevins JE, Larsson J, Permert J, Westermark P, Reidelberger RD, Adrian TE: Effects of acute and chronic infusion of islet amyloid polypeptide on food intake in rats. Scand J Gastroenterol 1996;31:83-89.
54. Lutz TA, Geary N, Szabady MM, Delprete E, Scharrer E: Amylin decreases meal size in rats. Physiol Behav 1995;58:1197-1202.
55. Morley JE, Flood JF: Amylin decreases food intake in mice. Peptides 1991;12:865-869.
56. Morley JE, Suarez MD, Mattamal M, Flood JF: Amylin and food intake in mice - Effects on motivation to eat and mechanism of action. Pharmacol Biochem Behav 1997;56:123-129.
57. MacIntyre I: Amylin-amide, bone conservation and pancreatic β-cells. Lancet 1989;ii:1026-1027.
58. Zaidi M, Datta HK, Bevis PJ, Wimalawansa SJ, MacIntyre I: Amylin-amide: A new bone-conserving peptide from the pancreas. Exp Physiol 1990;75:529-536.
59. Zaidi M, Shankar VS, Huang CLH, Pazianas M, Bloom SR: Amylin in bone conservation Current evidence and hypothetical considerations. Trends Endocrinol Mctab 1993;4:255-259.
60. Cornish J, Callon KE, Cooper GJ, Reid IR: Amylin stimulates osteoblast proliferation and increases mineralised bone volume in adult mice. Biochem Biophys Res Commun 1995;207: 133-139.
61. Alam AS, Moonga BS, Bevis PJ, Huang CL, Zaidi M: Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. Exp Physiol 1993;78:183-196.
62. Gebre-Medhin S, Mulder H, Pekny M, Tornell J, Sundler F, Westermark P, Ahren B, Betsholtz C: Accelerated glucose elimination in IAPP/ amylin knockout mice. Diabetes 1996; 46(suppl 1):A56.
63. Frontoni S, Choi SB, Banduch D, Rossetti L: In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 1991;40:568-573.
64. Clark A, de Koning EJ, Hattersley AT, Hansen BC, Yajnik CS, Poulton J: Pancreatic pathology in non-insulin-dependent diabetes (NIDDM). Diabetes Res Clin Pract 1995;28:8168-8227.
65. Wookey PJ, Cao Z, van Geenen RCI, Voskuil M, Darby IA, Komers R, Cooper ME: Increased density of renal amylin binding sites in experimental hypertension. Hypertension 1997;30: 455-460.
66. Harris PJ, Cooper ME, Hiranyachattada S, Berka JL, Kelly DJ, Nobes M, Wookey PJ: Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney. Am J Physiol 1997;272:F13-F21.
67. Williams B: Insulin resistance: The shape of things to come. Lancet 1994;344:521-524.
68. Young AA, Rink TJ, Vine W, Gedulin B: Amylin and syndrome-X. Drug Dev Res 1994;32:90-99.
69. Cooper ME, Wookey PJ: Amylin Its role in the kidney. Nephrol Dial Transplant 1997;12: 8-10.
70. Wookey PJ, Cooper ME: Amylin: Physiological roles in the kidney and a hypothesis for its role in hypertension. Clin Exp Pharmacol Physiol 1998;25:653-660.
71. Kolterman OG, Gottlieb A, Moyses C, Colburn W: Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC 137, a human amylin analogue. Diabetes Care 1995;18:1179-1182.
72. Chai SY, Christopoulos G, Cooper M, Sexton PM: Localisation and characterisation of renal binding sites for amylin, calcitonin and calcitonin gene-related peptide in primate kidney. Am J Physiol 1998;274:F51-F62.
73. Young AA, Nuttall A, Moyses C, Percy A, Vine W, Rink T: Amylin stimulates the renin-angiotensin-aldosterone axis in rats and man (abstract). Diabetologia 1995;38(suppl 1):A225.
74. Cooper ME, McNally PG, Phillips PA, Johnston CI: Amylin stimulates plasma renin concentration in humans. Hypertension 1995;26: 460-464.
75. Blakely P, Vaughn DA, Fanestil DD: Amylin, calcitonin gene-related peptide and adrenomedullin: Effects on thiazide receptor and calcium. Am J Physiol 1997;272:F410-F415.
76. Miles PD, Deftos LJ, Moossa AR, Olefsky JM: Islet amyloid polypeptide (amylin) increases the renal excretion of calcium in the conscious dog. Calcif Tissue Int 1994;55:269-273.
77. Hammerman M: New treatments for acute renal failure: Growth factors and beyond. Curr Opin Nephrol Hypertens 1997;6:7-9.
78. Safirstein R: Gene expression in nephrotoxic and ischaemic acute renal failure. J Am Soc Nephrol 1994;4:1387-1395.
79. Toback F: Regeneration after acute tubular necrosis. Kidney Int 1992;41:226-246.
80. Garcia Ocana A, Ortega J, Gonzalez Garcia Y, Carcia Canton C, Esbrit P: Partial purification of a renotropic activity from plasma of uninephrectomized human subjects. Nephron 1993;64:547-551.
81. Fine LG, Hammerman MR, Abboud HE: Evolving role of growth factors in the renal response to acute and chronic disease. J Am Soc Nephrol 1992;2:1163-1170.
82. Pollock CA, Fields MJ: Compensatory renal hypertrophy: Tubular cell growth and transport studied in primary culture. Nephron 1993;64: 615-620.
83. Datta H, Rafter P, Chen Z, Wimilawansa S, Macintyre I: Amylin-amide displays a proliferativc effect on human umbilical vein endothelial cells. Biochem Soc Trans 1990;18:1276.
84. Grobstein C: Inductive interaction in the development of the mouse metanephros. J Exp Zool 1955;130:319-340.
85. Gossens CL, Unsworth BR: Evidence for a two-step mechanism operating during in vitro mouse kidney tubulogenesis. J Embryol Exp Morphol 1972;28:615-631.
86. Sorokin L, Ekblom P: Development of tubular and glomerular cells of the kidney. Kidney Int 1992;41:657-664.
87. Woolf AS, Kolasti-Joannou M, Hardman P, Andermarcher E, Moorby C, Fine LG, Jat PS, Noble MD, Gherardi E: Roles of hepatocyte growth factor/scatter factor and the Met receptor in early development of the metanephros. J Cell Biol 1995;128:171-184.
88. Cantley LG: Growth factors and the kidney: Regulation of epithelial cell movement and morphogenesis. Am J Physiol 1996;271:F1103-F1113.
89. Nadasdy T, Laszik Z, Blick KE, Johnson DL, Burst Singer K, Nast C, Cohen AH, Ormos J, Silva FG: Human acute tubular necrosis: A lectin and immunohistochemical study. Hum Pathol 1995;26:230-239.
90. Ekblom P, Miettinen A, Saxen L: Induction of brush border antigens of the proximal tubule in the developing kidney. Dev Biol 1980;74:263-274.
91. Hammerman MR: Growth factors in renal development. Semin Nephrol 1995;15:291-299.
92. Ramirez I, Tebar F, Grau M, Soley M: Role of heterotrimeric G-proteins in epidermal growth factor signalling. Cell Signal 1995;7:303-311.
93. Haynes J, Hodgson W, Cooper ME: Rat amylin mediates a pressor effect in the anaesthetised rat. Diabetologia 1997;40:256-261.
94. Bhaysar S, Young A: The selective amylin antagonist. AC413, prevents sucrose-induced increases in mean arterial pressure in rats. Am J Hypertens 1995:8:55A.
95. Cao Z, Wookey P, Wu L, Voskuil M, van Geenen R, Cooper M: Renal amylin binding in normotensive and hypertensive rats: Effects of angiotensin-converting enzyme inhibition with perindopril. J Hypertens 1997;15:1245-1252.
96. Lutz TA, Rand JS: Plasma amylin and insulin concentrations in normoglycemic and hyperglycemic cats. Can Vet J 1996;37:27-34.
97. Sakagashira S, Sanke T, Hanabusa T, Shimomura H, Ohagi S, Kumagaye KY, Nakajima K, Nanjo K: Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 1996;45:1279-1281.
98. Harris RC, Cheng H-F: The intrarenal reninangiotensin system: A paracrine system for the local control of renal function separate from the systemic axis. Exp Nephrol 1996;4(suppl 1 ):2-7.
99. Anderson S, Jung FF, Ingelflnger JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993;265:F477-F486.
100. Ingelfinger JR, Min Zuo W, Fon EA, Ellison KE, Dzau VJ: In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. J Clin Invest 1990;85:417-423.
101. Darby IA, Sernia C: In situ hybridization and immunohistochemistry of renal angiotensinogen in neonatal and adult rat kidneys. Cell Tissue Res 1995;281:197-206.
102. Darby IA, Congiu M, Fernley RT, Sernia C, Coghlan JP: Cellular and ultrastructural location of angiotensinogen in rat and sheep kidney. Kidney Int 1994;46:1557-1560.
103. Maric C, Aldred GP, Antoine AM, Dean RG, Eitle E, Mendelsohn FAO, Williams DA, Harris PJ, Alcorn D: Effects of angiotensin II on cultured rat renomedullary interstitial cells are mediated by AT1A receptors. Am J Physiol 1996;271:F1020-F1028.
104. Chen M, Harris MP, Rose D, Smart A, He X-R, Kretzier M, Briggs JP, Schnermann J: Renin and renin mRNA in proximal tubules of the rat kidney. J Clin Invest 1994;94:237-243.
105. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G: Glomerularfiltration rate in the streptozocin diabetic rat: The role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes 1990;38:1182-1190.
106. Norman TJ: The role of angiotensin II in renal growth. Renal Physiol Biochem 1991;14:175-185.
107. Niimura F, Labosky PA, Kakuchi J, Okubo S, Yoshida H, Oikawa T, Ichiki T, Naftilan AJ, Fogo A, Inagami T, Hogan BLM, Ichikawa I: Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995;96:2947-2954.
108. Guron G, Adams MA, Sundelin B, Friberg P: Neonatal angiotensin-converting enzyme inhibition in the rat induces persistent abnormalities in renal function and histology. Hypertension 1997;29:91-97.
109. Letterio JJ, Bottinger EP: TGF-β knockout and dominant-negative receptor transgenic mice. Miner Electrolyte Metab 1998;24:161-167.
110. Ando T, Okudo S, Yanagida T, Fujishima M: Localization of TGF-β and its receptors in the kidney. Miner Electrolyte Metab 1998;24: 149-153.
111. Border WA: Transforming growth factor-beta and the pathogenesis of glomerular diseases. Curr Opin Nephrol Hypertens 1994;3:54-58.
112. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen L, Jerums G, Cooper ME: Expression of transforming growth faclor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of angiotensin converting enzyme inhibition. Diabetes 1998;47:414-422.
113. Eddy A: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495-2508.